ES2116726T3 - Cianoguanidinas utilizadas como bloqueadores del canal k. - Google Patents

Cianoguanidinas utilizadas como bloqueadores del canal k.

Info

Publication number
ES2116726T3
ES2116726T3 ES95907285T ES95907285T ES2116726T3 ES 2116726 T3 ES2116726 T3 ES 2116726T3 ES 95907285 T ES95907285 T ES 95907285T ES 95907285 T ES95907285 T ES 95907285T ES 2116726 T3 ES2116726 T3 ES 2116726T3
Authority
ES
Spain
Prior art keywords
pct
hydrogen
c3alkyl
sec
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95907285T
Other languages
English (en)
Inventor
Stephen J Humphrey
Kaushik D Meisheri
James H Ludens
Jackson B Hester Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Application granted granted Critical
Publication of ES2116726T3 publication Critical patent/ES2116726T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPUESTOS DE CIANOGUANIDINA DE FORMULA (I) Y SUS SALES DE ADICION ACIDAS ACEPTABLES FARMACEUTICAMENTE DONDE R{SUB,1} ES HIDROGENO O METILO; R{SUB,2} ES ALQUILO C{SUB,1}-C{SUB,6}, ALQUENILO C{SUB,2}-C{SUB,6}, CICLOALQUIL C{SUB,3}-C{SUB,5} ALQUINILO C{SUB,2}-C{SUB,6}, CICLOALQUENILO C{SUB,3}-C{SUB,5}, HIDROXIMETILO, ALQUIL C{SUB,1}-C{SUB,5} METOXI, O R{SUB,1} Y R{SUB,2} SON COMBINADOS PARA FORMAR UN ANILLO CARBOXILICO C{SUB,3}-C{SUB,6}; R{SUB,3} Y R{SUB,4} SON INDEPENDIENTEMENTE CADA UNO SELECCIONADOS PARA SER HIDROGENO, ALQUILO C{SUB,1}C{SUB,4}, F, CL, BR, I O CF{SUB,3}; R{SUB,5} ES HIDROGENO, F O CL; R{SUB,6} ES HIDROGENO, NH{SUB,2}, NHCH{SUB,3}, NHC{SUB,2}H{SUB,5}, NHCH(CH{SUB,3}){SUB,2}, N(CH{SUB,3}){SUB,2}, N(C{SUB,2}H{SUB,5}){SUB,2}, NH(CH{SUB,2}){SUB,M}OALQUILOC{SUB,1}C{SUB,3}, NHC(O)ALQUILOC{SUB,1}-C{SUB,3}, F, CL, BR, ALQUILO C{SUB,1}-C{SUB,3}, NH(CH{SUB,2}){SUB,M}F, 1-IMIDAZOLILO, NHOALQUILOC{SUB,1}-C{SUB,3}, NHOH, NHSO{SUB,2}ALQUILOC{SUB,1}C{SUB,3}, SH, SALQUILOC{SUB,1}-C{SUB,3},NHC(O)OALQUILOC{SUB,1}C{SUB,3}, NHC(O)NHALQUILOC{SUB,1}-C{SUB,3}, NHSO{SUB,2}NHALQUILOC{SUB,1}-C{SUB,3}, NHSO{SUB,2}N(ALQUILO C{SUB,1}-C{SUB,3}){SUB,2} O AMIDA DE AMINOACIDO; R{SUB,7} ES ALQUILO C{SUB,1}-C{SUB,7}, NH{SUB,2}, NHALQUILOC{SUB,1}-C{SUB,3}, N(ALQUILO C{SUB,1}-C{SUB,3}){SUB,2}, CF{SUB,3}, F, CL, BR, I, OALQUILO C{SUB,1}-C{SUB,3}, OH, COOH, C(O)OALQUILO C{SUB,1}C{SUB,3}, C(O)NH{SUB,2}, C(O)NHALQUILO C{SUB,1}-C{SUB,3}, C(O)ALQUILO C{SUB,1}-C{SUB,3} C(O)N(ALQUILO C{SUB,1}C{SUB,3}){SUB,2}, SO{SUB,2}NH{SUB,2}, SO{SUB,2}NHALQUILO C{SUB,1}-C{SUB,3}, CN, SO{SUB,2}N(ALQUILO C{SUB,1}C{SUB,3}){SUB,2}, NHC(O)ALQUILO C{SUB,1}-C{SUB,3}, NHC(O)NHALQUILO C{SUB,1}-C{SUB,3}, NHC(O)N(ALQUILO C{SUB,1}C{SUB,3}){SUB,2}, NHSO{SUB,2}NHALQUILO C{SUB,1}-C{SUB,3}, NHSO{SUB,2}N(ALQUILO C{SUB,1}-C{SUB,3}){SUB,2}, SH, SALQUILO C{SUB,1}-C{SUB,3}, NO{SUB,2}, SO{SUB,2}ALQUILO C{SUB,1}-C{SUB,3}, NHC(O)OALQUILO C{SUB,1}-C{SUB,3}, AMIDA DE AMINOACIDO O HIDROGENO; R{SUB,8} ES HIDROGENO, ALQUILO C{SUB,1}-C{SUB,6}, NH{SUB,2}, NHALQUILO C{SUB,1}-C{SUB,3}, N(CH{SUB,3}){SUB,2}, N(C{SUB,2}H{SUB,5}){SUB,2}, F, CL, BR, OALQUILO C{SUB,1}-C{SUB,3} U OH; Y DONDE M ES 2 O 3 Y N ES 0 O 1 (EXCEPTO PARA ESOS COMPUESTOS DONDE R{SUB,8} ES HIDROGENO Y R{SUB,6} ES HIDROGENO, NH{SUB,2}, NHCH{SUB,3}, NHC{SUB,2}H{SUB,5}, NHCH(CH{SUB,3}){SUB,2}, N(CH{SUB,3}){SUB,2}, N(C{SUB,2}H{SUB,5}){SUB,2}, NH(CH{SUB,2}){SUB,M}-OALQUILO C{SUB,1}-C{SUB,3}, NHC(O)ALQUILO C{SUB,1}-C{SUB,3}, CL O BR. LOS COMPUESTOS DE FORMULA (I) SON BLOQUEADORES DEL CANAL DE POTASIO UTILES EN EL TRATAMIENTO DE TRASTORNOS CARDIOVASCULARES TALES COMO INSUFICIENCIA CARDIACA CONGESTIVA E HIPERTENSION Y COMO UN DIURETICO.
ES95907285T 1994-01-28 1995-01-09 Cianoguanidinas utilizadas como bloqueadores del canal k. Expired - Lifetime ES2116726T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18896994A 1994-01-28 1994-01-28

Publications (1)

Publication Number Publication Date
ES2116726T3 true ES2116726T3 (es) 1998-07-16

Family

ID=22695331

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95907285T Expired - Lifetime ES2116726T3 (es) 1994-01-28 1995-01-09 Cianoguanidinas utilizadas como bloqueadores del canal k.

Country Status (11)

Country Link
US (1) US5668157A (es)
EP (1) EP0741708B1 (es)
JP (1) JPH09508382A (es)
AT (1) ATE166343T1 (es)
AU (1) AU1556695A (es)
CA (1) CA2179036A1 (es)
DE (1) DE69502584T2 (es)
DK (1) DK0741708T3 (es)
ES (1) ES2116726T3 (es)
MX (1) MX9603051A (es)
WO (1) WO1995020579A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711126D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Cyanoamidines
GB9711127D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711124D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711123D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711125D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
WO2000061561A1 (en) 1999-04-09 2000-10-19 Shionogi Bioresearch Corp. Cyanoguanidine compounds
AU5542101A (en) 2000-04-14 2001-10-30 Univ Vanderbilt Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
CA2437400A1 (en) * 2001-02-07 2002-08-15 Abbott Laboratories Aminal diones as potassium channel openers
US9296697B2 (en) * 2005-08-24 2016-03-29 Abbott Laboratories Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors
US20220324809A1 (en) * 2019-09-03 2022-10-13 Salzman Group Ltd. Atp-regulated potassium channel openers and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2361052C2 (de) * 1973-12-07 1982-12-30 Ruhrchemie Ag, 4200 Oberhausen Verfahren zur Polymerisation von α-Olefinen mit 2 bis 6 Kohlenstoffatomen
GB1489879A (en) * 1974-12-20 1977-10-26 Leo Pharm Prod Ltd N'-cyano-n'-3-pyridylguanidines
US5006523A (en) * 1989-10-26 1991-04-09 E. R. Squibb & Sons, Inc. Antiarrhythmic agents: aryl cyanoguanidine potassium channel blockers
JPH03166119A (ja) * 1989-11-24 1991-07-18 Showa Alum Corp パイプの転送装置
JPH05294935A (ja) * 1991-03-15 1993-11-09 Green Cross Corp:The アミノピリジン系化合物
AU4530693A (en) * 1992-08-13 1994-03-15 Upjohn Company, The Cyanoguanidines as potassium channel blockers
US5401758A (en) * 1993-10-07 1995-03-28 Bristol-Myers Squibb Company Pyridinyl cyanoguanidine compounds

Also Published As

Publication number Publication date
MX9603051A (es) 1997-06-28
AU1556695A (en) 1995-08-15
ATE166343T1 (de) 1998-06-15
CA2179036A1 (en) 1995-08-03
DE69502584T2 (de) 1998-11-26
WO1995020579A1 (en) 1995-08-03
EP0741708B1 (en) 1998-05-20
US5668157A (en) 1997-09-16
DE69502584D1 (de) 1998-06-25
DK0741708T3 (da) 1999-01-18
JPH09508382A (ja) 1997-08-26
EP0741708A1 (en) 1996-11-13

Similar Documents

Publication Publication Date Title
MY135841A (en) Novel benzodioxoles
MY136926A (en) Glucokinase activators
ES2116726T3 (es) Cianoguanidinas utilizadas como bloqueadores del canal k.
FI990419A0 (fi) Typpeä sisältävien hetrosyklisten yhdisteiden fluorialkoksibentsyyliaminojohdannaiset
SG159380A1 (en) Heteroaryl compounds useful as inhibitors of gsk-3
PE20001421A1 (es) Sulfonamidas heterociclicas como inhibidores de endotelina
MY133393A (en) Phenyl xanthine derivatives
TR199802060T2 (xx) Aminoisokinolinler ve aminopiridin t�revlerinin iltihap �nleyiciler olarak kullan�m�.
AR007352A1 (es) Derivados sustituidos de bencimidazol, proceso para su preparacion, formulacion farmaceutica que los contiene, y uso de dichos derivados para la manufactura de medicamentos
TR200102008T2 (tr) Serebral işemi profilaksı ve tedavisi için piridin türevlerinin kullanımı.
MY110826A (en) Cyanoguanidines as k-channel blockers
NO20052751L (no) Oftalmisk preparat for behandling av okulaer hypertensjon.
IT1271411B (it) Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare
ATE201400T1 (de) Chinazolinylamino derivate mit alfa-antagonist wirkung
DE69102762D1 (de) Beta-phenylisoserinderivate, ihre herstellung und ihre anwendung.
DK0720598T3 (da) Phenoxyphenylcyclopentenyl-hydroxyurinstoffer
ATE216891T1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
NO942775L (no) 3-fenylureido-azepin-2-oner og -benzazepin-2-oner anvendelige som cholecystokinin-antagonister
DK0678088T3 (da) N-acylpyrrolidiner og lægemidler til behandling og forebyggelse af cholecystokinin- og gastrinrelaterede sygdomme
TR199900013T2 (xx) Yeni bile�ikler.
GR3029737T3 (en) Pyrimidine cyanoguanidines as k-channel blockers
ATE134632T1 (de) Optisch aktives hydrochinin (amino-3-phenyl)-1- ethansulfonat, deren herstellung und verwendung
MX9704299A (es) Derivados de bencimidazol.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 741708

Country of ref document: ES